Tetanus Toxoid
- Atc Codes:J07AM01
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Genes that may be involved
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Tetanol Pur, Tetanus-Adsorbat; Bulgaria: Tetatox, Tetavax; Cyprus: Tetavax; Czech Republic: Alteana, Tetanol Pur, Tetavax; Denmark: Tetanusvaccine; Estonia: Tetavax; Germany: Tetanol; Greece: Tetaniko; Italy: Anatetall, Imovax Tetano; Luxembourg: Anatoxal T; Malta: Tetavax; Netherlands: Tetanusvaccin; Romania: Tetavax, Vaccin Tetanic Adsorbit; Slovakia: Tetavax.
Latin America
Argentina: Tetavax, Vacuna Antitetánica; Brazil: Toxóide Tetânico; Mexico: Tetanol, Tetinox.
Asia
Japan: Adsorbed Tetanus Toxoid.
Drug combinations
Tetanus Toxoid and Diphtheria Toxoid
Tetanus Toxoid, Diphtheria Toxoid, and Poliovirus (Type 1, 2, and 3)
Tetanus Toxoid, Bordetella pertussis, Diphtheria Toxoid, Haemophilus influenza b Conjugate Vaccine, and Pertactin
Tetanus Toxoid, Bordetella pertussis, Diphtheria Toxoid, and Hepatitis B Vaccine
Tetanus Toxoid, Bordetella pertussis, Diphtheria Toxoid, Haemophilus influenzae type B Polysaccharide, and Hepatitis B Surface Antigen (Recombinant)
Tetanus Toxoid, Bordetella pertussis, Diphtheria Toxoid, Haemophilus influenza b Conjugate Vaccine, Hepatitis B surface Antigen (HbsAg), Pertactin, Poliovirus type 1 (Mahoney), Poliovirus type 2 (MEF 1), and Poliovirus type 3 (Saukett)
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Toxoids. (ATC-Code: J07AM01).
Mechanism of action
Tetanus toxoid preparations contain toxin produced by virulent tetanus bacilli (detoxified growth products of Clostridium tetani). Toxin modified by treatment with formaldehyde so that it has lost toxicity but still retains ability to act as antigen and produce active immunity.
Therapeutic use
Indicated as booster dose in active immunization against tetanus in rare adult or child allergic to aluminum adjuvant (product containing adsorbed tetanus toxoid is preferred). Not indicated for primary immunization.
Pregnancy and lactiation implications
Reproduction studies not conducted and effects to fetus not known. Deferring immunization until 2^nd^ trimester may be considered.
Unlabeled use
Anergy testing (no longer recommended).
Contraindications
Hypersensitivity to tetanus toxoid or any component of the formulation.
Warnings and precautions
Anaphylactoid and/or hypersensitivity reactions might occur. Further routine or emergency doses of tetanus and diphtheria toxoids should not be given to patients with history of severe local reaction (Arthus-type) or temperature of >39.4 ˚C (>103 ˚F) following previous dose, for 10 years. Immunization should be delayed during the course of acute febrile illness. Use with caution in history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy (bleeding/hematoma may occur from I.M. administration). SubQ administration may be preferred. Defer elective immunization during outbreaks of poliomyelitis. Patients who are immunocompromised may have reduced response. May be used in HIV infection. Vial stopper may contain natural latex rubber. Product may contain thimerosal.